Cytomed Therapeutics Limited Stock Today
| GDTC Stock | 3.45 0.05 1.43% |
Performance11 of 100
| Odds Of DistressLess than 20
|
CytoMed Therapeutics is trading at 3.45 as of the 6th of January 2025, a 1.43 percent down since the beginning of the trading day. The stock's open price was 3.5. CytoMed Therapeutics has about a 20 % chance of experiencing some form of financial distress in the next two years of operation and had a somewhat good performance during the last 90 days. The performance scores are derived for the period starting the 11th of April 2024 and ending today, the 6th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 14th of April 2023 | Category Healthcare | Classification Health Care |
CytoMed Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 11.54 M outstanding shares of which 62.69 K shares are currently shorted by private and institutional investors with about 4.21 trading days to cover. More on CytoMed Therapeutics Limited
Moving against CytoMed Stock
| 0.55 | DNLI | Denali Therapeutics Downward Rally | PairCorr |
| 0.55 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.42 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.39 | UPC | Universe Pharmaceuticals | PairCorr |
| 0.31 | PFE | Pfizer Inc Sell-off Trend | PairCorr |
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
CytoMed Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Executive Chairman | Chee Choo | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
CytoMed Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand CytoMed Therapeutics' financial leverage. It provides some insight into what part of CytoMed Therapeutics' total assets is financed by creditors.
| |||||
CytoMed Therapeutics Limited (GDTC) is traded on NASDAQ Exchange in USA. It is located in 1 Commonwealth Lane, No. 08-22, Singapore, Singapore, 149544 and employs 8 people. CytoMed Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 26.17 M. CytoMed Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 11.54 M outstanding shares of which 62.69 K shares are currently shorted by private and institutional investors with about 4.21 trading days to cover.
CytoMed Therapeutics generates negative cash flow from operations
Check CytoMed Therapeutics Probability Of Bankruptcy
Ownership AllocationThe market capitalization of CytoMed Therapeutics is USD26.17 Million. CytoMed Therapeutics Limited shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 69.27 percent of CytoMed Therapeutics outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check CytoMed Ownership Details
CytoMed Therapeutics Historical Income Statement
CytoMed Stock Against Markets
CytoMed Therapeutics Corporate Directors
| Jieming Zeng | Chief Director | Profile | |
| Tien Luk | Chief Director | Profile | |
| Jieming MD | Chief Director | Profile | |
| Wee Tan | COO Director | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in CytoMed Therapeutics Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytoMed Therapeutics. If investors know CytoMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytoMed Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.22) | Revenue Per Share | Quarterly Revenue Growth (0.21) | Return On Assets | Return On Equity |
The market value of CytoMed Therapeutics is measured differently than its book value, which is the value of CytoMed that is recorded on the company's balance sheet. Investors also form their own opinion of CytoMed Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytoMed Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytoMed Therapeutics' market value can be influenced by many factors that don't directly affect CytoMed Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytoMed Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytoMed Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytoMed Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.